Kim YH, Bagot M, Pinter-Brown L, et al. Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): Results from the Phase III MAVORIC Study. ASH 59th Annual Meeting & Exhibition, abstract 817.
Etranacogene dezaparvovec bij hemofilie B: effectiviteit en veiligheid na 24 maanden
apr 2024 | Benigne hematologie